Abstract
|
Ischemia-Modified Albumin and Inflammatory Biomarkers in Patients with Prostate Cancer
by Rafael Arrua Da Silveira, Carine Lima Hermes, Tais Correa Almeida, Guilherme Vargas Bochi, Karine Santos De Bona, Maria Beatriz Moretto, Rafael Noal Moresco
|
|
|
Background: Prostate cancer has become a public health problem in many countries and there is evidence which indicates that inflammation and oxidative stress play a key role in the pathogenesis of this disease. Thus, the aim of this study was to evaluate the concentrations of new biomarkers of oxidative stress, ischemia-modified albumin (IMA) and ferric reducing ability of plasma (FRAP), as well as the inflammatory markers in patients with prostate cancer.
Methods: CRP, IMA, FRAP, fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, uric acid, creatinine, albumin, AST, ALT, ADA, total PSA (tPSA), free PSA, and proportion of free PSA (fPSA%) were measured in 25 patients with prostate cancer and in 30 healthy subjects.
Results: tPSA, CRP, and IMA were significantly higher in patients with prostate cancer. In contrast, fPSA% and FRAP were significantly lower in these patients. However, no significant differences were observed when IMA values were adjusted for serum albumin. Significant correlations were also observed for tPSA and CRP (r = 0.5104, p < 0.001) and for fPSA% and CRP (r = -0.5059, p < 0.001).
Conclusions: We demonstrated that both inflammatory and oxidative processes are increased during prostate cancer and also that there is a reduction of antioxidant defenses in this pathology.
DOI: 10.7754/Clin.Lab.2014.131018
|
